Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 4:16:3641-3649.
doi: 10.2147/OPTH.S388886. eCollection 2022.

Glaucoma and Ocular Surface Disease: More than Meets the Eye

Gavin Li  1 , Esen Karamursel Akpek  2 , Sumayya Ahmad  1
Affiliations
Review

Glaucoma and Ocular Surface Disease: More than Meets the Eye

Gavin Li et al. Clin Ophthalmol. .

Abstract

Understanding the association between ocular surface disease and glaucoma is important for improving adherence to treatment and introducing practical solutions. While topical antihypertensive medications for glaucoma are well tolerated according to short-term studies, there is little evidence on their long-term effects. Since they are often required for many years, the effects of these drops on the ocular surface become important in regard to quality of life and adherence. In this nonsystematic review performed in April 2022, we summarize what is known about the relationship between glaucoma and ocular surface disease. Specifically, we examine how each class of topical glaucoma drops affects the ocular surface. We then review the treatment of ocular surface disease for patients on topical glaucoma therapy. Finally, we discuss treatments that may reduce or eliminate the burden of topical medications.

Keywords: adherence; glaucoma; ocular surface disease.

PubMed Disclaimer

Conflict of interest statement

Dr Esen Karamursel Akpek reports grants from National Eye Institute, Ocular Therapeutics, Novartis, W.L. Gore Inc, IRIS Registry Research Fund, Department of Defence; non-financial support from Adelphi Values, Dompe, FirstString Medical Research, HanAll, Novalique, Regeneron Healthcare Solutions, Sinqi, Xequel, Kyria, and Hawkeye, outside the submitted work. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013 - DOI - PubMed
    1. Heijl A, Leske MC, Hyman L, Yang Z, Bengtsson B, Group E. Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. Acta Ophthalmol. 2011;89(8):749–754. doi:10.1111/j.1755-3768.2009.01852.x - DOI - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. - PubMed
    1. Duru Z, Ozsaygili C. Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. Cutan Ocul Toxicol. 2020;39(1):21–24. doi:10.1080/15569527.2019.1680685 - DOI - PubMed
    1. Konstas AG, Labbé A, Katsanos A, et al. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opin Drug Saf. 2021;20(4):453–466. doi:10.1080/14740338.2021.1873947 - DOI - PubMed